Khanna, D., Wilson, H. G., Kanetkar, J., Tan, J. K., Marra, D., Plant, J., Irfan, S., Benny, O., Parkes, J., Mohapatra, S., Shaw, H. M., Ponda, N., O'Carrigan, B., Olsson-Brown, A., Ghose, A., Frazer, R. D. (2026). Dual immune checkpoint inhibition vs anti–PD-1 monotherapy in metastatic
                    <i>BRAF</i>
                    wild-type/undetermined melanoma: Ethnicity-based benchmarking of treatment endpoints in 2,659 patients.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e21512